CY1107852T1 - Νεες χρησεις αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη της ημικρανιας - Google Patents

Νεες χρησεις αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη της ημικρανιας

Info

Publication number
CY1107852T1
CY1107852T1 CY20081100040T CY081100040T CY1107852T1 CY 1107852 T1 CY1107852 T1 CY 1107852T1 CY 20081100040 T CY20081100040 T CY 20081100040T CY 081100040 T CY081100040 T CY 081100040T CY 1107852 T1 CY1107852 T1 CY 1107852T1
Authority
CY
Cyprus
Prior art keywords
treatment
migrania
aminoxic
sprayers
new uses
Prior art date
Application number
CY20081100040T
Other languages
English (en)
Inventor
Robert H Harris
Original Assignee
Research Corporation Technologies, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corporation Technologies, Inc filed Critical Research Corporation Technologies, Inc
Publication of CY1107852T1 publication Critical patent/CY1107852T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Στην παρούσα εφεύρεση περιγράφεται η χρήση μιας ένωσης του ακόλουθου τύπου (I) για την παρασκευή ενός φαρμάκου αποτελεσματικού στη θεραπευτική αγωγή ή πρόληψη ημικρανιακών κεφαλαλγιών σε ένα θηλαστικό:
CY20081100040T 2000-08-25 2008-01-11 Νεες χρησεις αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη της ημικρανιας CY1107852T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22823000P 2000-08-25 2000-08-25
EP04021727A EP1486205B1 (en) 2000-08-25 2001-08-24 Use of anticonvulsant aminoacids for the treatment of migraine

Publications (1)

Publication Number Publication Date
CY1107852T1 true CY1107852T1 (el) 2013-06-19

Family

ID=22856332

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20071100768T CY1107668T1 (el) 2000-08-25 2007-06-11 Χρηση αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη του πονου
CY20081100041T CY1107853T1 (el) 2000-08-25 2008-01-11 Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων
CY20081100040T CY1107852T1 (el) 2000-08-25 2008-01-11 Νεες χρησεις αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη της ημικρανιας
CY200900002C CY2009002I1 (el) 2000-08-25 2009-02-18 Χρηση αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη του πονου
CY20101101002T CY1112349T1 (el) 2000-08-25 2010-11-04 Αντισπασμωδικα αμινοξεα για τη θεραπευτικη αγωγη ψυχαναγκαστικης-καταναγκαστικης νευρωσης

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20071100768T CY1107668T1 (el) 2000-08-25 2007-06-11 Χρηση αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη του πονου
CY20081100041T CY1107853T1 (el) 2000-08-25 2008-01-11 Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY200900002C CY2009002I1 (el) 2000-08-25 2009-02-18 Χρηση αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη του πονου
CY20101101002T CY1112349T1 (el) 2000-08-25 2010-11-04 Αντισπασμωδικα αμινοξεα για τη θεραπευτικη αγωγη ψυχαναγκαστικης-καταναγκαστικης νευρωσης

Country Status (13)

Country Link
US (6) US6884910B2 (el)
EP (5) EP1365787B1 (el)
JP (2) JP4307068B2 (el)
AT (4) ATE357227T1 (el)
AU (6) AU2001286763C1 (el)
CA (2) CA2740815C (el)
CY (5) CY1107668T1 (el)
DE (4) DE60142806D1 (el)
DK (4) DK1486206T3 (el)
ES (5) ES2281439T3 (el)
LU (1) LU91512I2 (el)
PT (4) PT1486205E (el)
WO (1) WO2002015922A2 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60142806D1 (de) * 2000-08-25 2010-09-23 Res Corp Technologies Inc Aminosäure enthaltende Antikonvulsiva zur Behandlung von Zwangsstörungen
EP1243262B1 (en) 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
EP1243263B1 (en) * 2001-03-21 2002-11-27 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US20050233472A1 (en) * 2003-09-19 2005-10-20 Kao H P Spotting high density plate using a banded format
EP1537862A1 (en) * 2003-12-02 2005-06-08 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
AU2004294714B2 (en) * 2003-12-02 2009-12-10 Ucb Pharma Gmbh Novel use of peptide compounds for treating central neuropathic pain
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
MXPA06011937A (es) 2004-04-16 2007-01-26 Sanol Arznei Schwarz Gmbh Uso de compuestos peptidicos para la profilaxis y el tratamiento de dolor de cabeza cronico.
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EP1629839A1 (en) * 2004-08-27 2006-03-01 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
BRPI0514721A (pt) 2004-08-27 2008-06-24 Sanol Arznei Schwarz Gmbh uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
SI2462990T1 (sl) * 2006-06-15 2014-04-30 Ucb Pharma Gmbh Farmacevtski sestavek, ki obsega lakozamid in levetiracetam, s sinergističnim antikonvulzivnim učinkom
US7489198B1 (en) 2007-04-26 2009-02-10 Lockheed Martin Corporation Linear regulating switch
WO2011101863A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
WO2015200322A1 (en) * 2014-06-23 2015-12-30 Northwestern University Methods of treating or ameliorating migraine
WO2017079169A1 (en) 2015-11-03 2017-05-11 Kimberly-Clark Worldwide, Inc. Paper tissue with high bulk and low lint
WO2019108172A1 (en) 2017-11-29 2019-06-06 Kimberly-Clark Worldwide, Inc. Fibrous sheet with improved properties
BR112021001335B1 (pt) 2018-07-25 2024-03-05 Kimberly-Clark Worldwide, Inc Método para fazer um substrato absorvente não tecido tridimensional (3d)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795788A (nl) * 1972-02-22 1973-08-22 Akzo Nv Werkwijze ter bereiding van peptiden en peptide-derivaten en de toepassing hiervan
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
FR2546517B1 (fr) * 1983-05-24 1987-04-24 Panmedica Nouveaux dipeptides du -l-5-hydroxy-tryptophane, procedes pour leur preparation et medicaments les contenant
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5331089A (en) * 1988-03-25 1994-07-19 Merck Sharpe & Dohme, Ltd. Peptides useful as tachykinin agonists
US5178729A (en) * 1991-01-15 1993-01-12 James River Corporation Of Virginia High purity stratified tissue and method of making same
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
AU5890394A (en) 1993-02-03 1994-08-29 Steven Andrew Jennings Blends of glycine derivatives and sugars
ES2154277T3 (es) * 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
US6348571B1 (en) * 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
EP0784629B1 (en) * 1994-10-05 1999-04-28 Darwin Discovery Limited Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6514937B1 (en) * 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
KR100522012B1 (ko) 1997-07-08 2005-10-18 오노 야꾸힝 고교 가부시키가이샤 아미노산 유도체
AU7937298A (en) 1997-07-08 1999-02-08 Ono Pharmaceutical Co. Ltd. Amino acid derivatives
AU744899B2 (en) 1997-07-15 2002-03-07 Research Corporation Technologies, Inc. Amino acid derivatives useful to treat stroke
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
RU2219924C2 (ru) * 1998-04-14 2003-12-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения нейропсихиатрических расстройств
ES2262322T3 (es) 1998-06-10 2006-11-16 Meiji Seika Kaisha, Ltd. Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar.
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6399574B1 (en) * 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
DE60142806D1 (de) 2000-08-25 2010-09-23 Res Corp Technologies Inc Aminosäure enthaltende Antikonvulsiva zur Behandlung von Zwangsstörungen
US6228825B1 (en) 2000-10-13 2001-05-08 Colgate Palmolive Company Automatic dishwashing cleaning system
EP1243262B1 (en) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain

Also Published As

Publication number Publication date
PT1365787E (pt) 2007-06-29
US20130316953A1 (en) 2013-11-28
PT1486205E (pt) 2008-01-25
US20040097416A1 (en) 2004-05-20
JP2009108090A (ja) 2009-05-21
JP2004506692A (ja) 2004-03-04
US6884910B2 (en) 2005-04-26
WO2002015922A3 (en) 2003-09-25
CY1107668T1 (el) 2010-07-28
EP1365787A2 (en) 2003-12-03
DK1365787T3 (da) 2007-07-23
PT1486206E (pt) 2008-01-25
LU91512I2 (fr) 2009-03-16
EP2210598B1 (en) 2013-09-18
CY2009002I2 (el) 2009-11-04
CY1107853T1 (el) 2013-06-19
PT1695703E (pt) 2010-11-16
ATE357227T1 (de) 2007-04-15
CY1112349T1 (el) 2015-12-09
WO2002015922A2 (en) 2002-02-28
AU2007202336B2 (en) 2009-09-24
DE60131032T2 (de) 2008-08-14
CA2419285C (en) 2011-08-02
EP1486205A1 (en) 2004-12-15
US7148378B2 (en) 2006-12-12
AU2007202336B9 (en) 2009-10-29
EP1695703A3 (en) 2006-12-13
ES2348646T3 (es) 2010-12-10
DE60127459T2 (de) 2007-07-12
EP1486206B1 (en) 2007-10-17
US20100273716A1 (en) 2010-10-28
DE60127459D1 (de) 2007-05-03
ATE375792T1 (de) 2007-11-15
AU2001286763B2 (en) 2005-11-24
AU2007202336A1 (en) 2007-06-14
CA2740815C (en) 2014-03-18
DE60131033T2 (de) 2008-07-17
AU2001286763C1 (en) 2006-03-02
DK1486205T3 (da) 2008-02-18
DK1695703T3 (da) 2010-10-25
US7186859B2 (en) 2007-03-06
CY2009002I1 (el) 2009-11-04
US20070142297A1 (en) 2007-06-21
AU2009202363B2 (en) 2011-02-17
AU8676301A (en) 2002-03-04
AU2009202362B2 (en) 2011-01-27
DE60131033D1 (de) 2007-11-29
US20040087508A1 (en) 2004-05-06
AU2009202362A1 (en) 2009-07-02
US8519183B2 (en) 2013-08-27
CA2740815A1 (en) 2002-02-28
ES2294414T3 (es) 2008-04-01
EP2210598A2 (en) 2010-07-28
ES2294415T3 (es) 2008-04-01
EP1365787B1 (en) 2007-03-21
US7772427B2 (en) 2010-08-10
ES2435000T3 (es) 2013-12-18
AU2009202363A1 (en) 2009-07-02
AU2011202293A1 (en) 2011-06-09
JP5190334B2 (ja) 2013-04-24
ES2281439T3 (es) 2007-10-01
ATE476971T1 (de) 2010-08-15
DE60142806D1 (de) 2010-09-23
US20020086828A1 (en) 2002-07-04
DK1486206T3 (da) 2008-02-11
ATE375793T1 (de) 2007-11-15
EP1486206A1 (en) 2004-12-15
EP1695703A2 (en) 2006-08-30
AU2011202293B2 (en) 2013-01-10
EP1695703B1 (en) 2010-08-11
EP1486205B1 (en) 2007-10-17
CA2419285A1 (en) 2002-02-28
DE60131032D1 (de) 2007-11-29
EP2210598A3 (en) 2011-07-20
JP4307068B2 (ja) 2009-08-05

Similar Documents

Publication Publication Date Title
CY1107852T1 (el) Νεες χρησεις αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη της ημικρανιας
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
SE0000540D0 (sv) New compounds
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
EA200801341A1 (ru) КОНДЕНСИРОВАННЫЕ БИЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ mTOR
BG106867A (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
ATE302775T1 (de) Carbolinderivate
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BG106585A (en) Kinase inhibitors as therapeutic agents
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
DE60334536D1 (de) Furylverbindungen
CY1110446T1 (el) Χρηση (ζ)-2-κυανο-3-υδροξυ-βουτ-2-ενοϊκου οξεος-(4’-τριφθορομεθυλοφαινυλο)-αμιδης για τη θεραπεια πολλαπλης σκληρωσης
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE346067T1 (de) Carbolinderivate
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore